Zura Bio Ltd (ZURA) FinancialsZURAZura Bio Ltd

Evaluating the bottom line, Zura Bio Ltd maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -72.10%, provide a clear picture of how effectively ZURA converts its operational activities into shareholder value.

In the context of the broader market, ZURA competes directly with industry leaders such as PROK and SCTX. With a market capitalization of $533.77M, it holds a significant position in the sector. When comparing efficiency, ZURA's gross margin of N/A stands against PROK's 100.00% and SCTX's N/A. Such benchmarking helps identify whether Zura Bio Ltd is trading at a premium or discount relative to its financial performance.

Zura Bio has reported consistent net losses, with a net income of -$24,223,000 for Q1 2026 and a forward P/E ratio of 0, indicating a lack of profitability. Despite this, the company has a strong current ratio of 19.33, suggesting good liquidity.